Clinical trials: Glaucoma Therapy
Glaucoma,Open-Angle, Ocular Hypertension
Non Interventional Study in Patients With Open Angle Glaucoma and/or Ocular Hypertension Treated With XALATAN®
The primary objective is to evaluate the Intraocular pressure reducing effect of Xalatan over 3 months. The secondary objective is to study the other efficacy parameters during treatment for 3 months
- Trial name
- NCT00486252
- Testing
- Observational
- Volunteers
- 996 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
The purpose of this study was to determine the incremental intraocular pressure (IOP) lowering that is achieved when Simbrinza is used adjunctively to Travatan in patients with normal tension glaucoma that may benefit from…
- Trial name
- NCT03150160
- Testing
- brinzolamide 1%/brimonidine 0.2% fixed combination, travoprost 0.004% ophthalmic solution
- Where
- South Korea
- Volunteers
- 1 people
- Sponsor
- Novartis Pharmaceuticals
Glaucoma
Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes
This is a randomized, double blind, two-arm, parallel group, active controlled bioequivalence study, at multiple clinical trial sites designed to demonstrate bioequivalence of Brinzolamide 1% ophthalmic suspension (manufactured…
- Trial name
- NCT02512042
- Testing
- Test-Brinzolamide 1% Ophthalmic suspension, Reference-Brinzolamide 1% Ophthalmic suspension
- Where
- 10 sites in United States
- Volunteers
- 973 people
- Sponsor
- Actavis Inc.
Open-Angle Glaucoma, Ocular Hypertension
Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-70
To compare intraocular pressure lowering effectiveness of a combination drug vs. two individual drugs dosed alone.
- Trial name
- NCT00047541
- Testing
- Alcon Investigational Agent
- Where
- United States
- Sponsor
- Alcon Research
Glaucoma
Success of Transitioning Uncontrolled Glaucoma Patients From Prior Mono or Adjunctive Therapy to DuoTrav
The purpose of this study is to assess the safety and efficacy of transitioning uncontrolled glaucoma patients to DuoTrav from other mono or adjunctive therapies.
- Trial name
- NCT00519753
- Testing
- Travoprost 0.004%/timolol maleate 0.5% fixed combination ophthalmic solution (DuoTrav)
- Where
- Germany
- Volunteers
- 522 people
- Sponsor
- Alcon Research
Glaucoma
Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy
Examine the safety, tolerability and efficacy of travoprost benzalkonium chloride (BAK) free ophthalmic solution compared to either latanoprost or bimatoprost monotherapy.
- Trial name
- NCT00444665
- Testing
- Travatan-Z
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- Alcon Research
Open Angle Glaucoma, Ocular Hypertension
Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT
The objective of the study is to evaluate evaluate the safety and IOP lowering efficacy of OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid in the treatment of subjects with open-angle…
- Trial name
- NCT02914509
- Testing
- Travoprost
- Where
- 10 sites in United States
- Volunteers
- 565 people
- Sponsor
- Ocular Therapeutix, Inc.
Refractory Glaucoma
Real-world Evidence Study of XEN in Chinese Patients With Refractory Glaucoma
Real-world evidence study to assess the safety and effectiveness of XEN® Glaucoma Treatment System in Chinese patients with refractory glaucoma.
- Trial name
- NCT04303897
- Testing
- XEN Glaucoma Stent
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Allergan
Glaucoma, Open-Angle, Ocular Hypertension
A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma
The purpose of this study is to evaluate the effect of latanoprost on intraocular pressure reduction in patients with ocular hypertension or open-angle glaucoma.
- Trial name
- NCT00647101
- Testing
- Latanoprost
- Where
- 176 sites in France
- Volunteers
- 600 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Glaucoma, Open Angle
SOLX Gold Shunt Versus Control Implant: Randomized Trial for Refractory Glaucoma
Study Objective: To establish the substantial equivalence of the SOLX Gold Shunt to commercially available aqueous shunts, specifically the Ahmed™ Glaucoma Valve Model FP7, in the ability to reduce intraocular pressure (IOP)…
- Trial name
- NCT00382395
- Testing
- SOLX Gold Shunt GMS-plus, Ahmed FP7 Glaucoma Valve
- Where
- 15 sites in United States, Canada and 3 more
- Volunteers
- 180 people
- Sponsor
- SOLX, Inc.
Open-angle Glaucoma, Ocular Hypertension
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
The purpose of the study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension
- Trial name
- NCT00293761
- Testing
- Travoprost, Investigational, Travoprost (TRAVATAN)
- Volunteers
- 109 people
- Sponsor
- Alcon Research
Primary Open Angle Glaucoma, Intraocular Pressure
Effects of Forskolin on Intraocular Pressure in Glaucomatous Patients Under Maximum Tolerated Medical Therapy
Elevated intraocular pressure is still the main risk factor for development and progression of glaucoma. Several drugs exist on the market that may decrease IOP in glaucomatous patients.
- Trial name
- NCT00864578
- Where
- Italy
- Sponsor
- Sooft Italia
Glaucoma
VividWhite Glaucoma Implant (VW-51) Pivotal Study
The VividWhite Glaucoma Implant (VW-51) is a novel surgical implant designed to treat glaucoma. This study is a 12-month, 65-participant non-comparative multicentre study to assess the safety and effectiveness of the VW-51…
- Trial name
- NCT06176170
- Testing
- VividWhite Glaucoma Implant (VW-51)
- Where
- 6 sites in Australia
- Volunteers
- 65 people
- Sponsor
- VividWhite Pty Ltd
Open-Angle Glaucoma, Ocular Hypertension
Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-02-41
To compare intraocular pressure lowering effectiveness of a combination drug vs. two individual drugs dosed alone.
- Trial name
- NCT00047528
- Testing
- Alcon Investigational Agent
- Where
- United States
- Sponsor
- Alcon Research
Glaucoma
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil
The purpose of this study was to assess the efficacy and tolerability of changing to AZARGA® from prior COMBIGAN® pharmacotherapy in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01514734
- Testing
- Brinzolamide/timolol maleate fixed combination
- Where
- Brazil
- Volunteers
- 9 people
- Sponsor
- Alcon Research
Open-angle Glaucoma
A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic Solution
The purpose of this study was to assess the pigmentation in the trabecular meshwork of patients who had been treated for at least 2 years with TRAVATAN compared with patients without exposure (or less than 1 month) to a…
- Trial name
- NCT01485822
- Testing
- Trabecular Meshwork Tissue Collection, Travoprost 0.004% ophthalmic solution
- Volunteers
- 88 people
- Sponsor
- Alcon Research
Glaucoma
Glaucoma Treatment by Cyclo-coagulation Using High Intensity Focused Ultrasound (HIFU)
The purpose of this study is to evaluate the effectiveness and the safety of the cyclocoagulation using High Intensity Focused Ulatrsound with the EYEOP1 device in glaucoma patients
- Trial name
- NCT01592955
- Testing
- EYEOP1
- Where
- 7 sites in Israel, Italy and 2 more
- Volunteers
- 84 people
- Sponsor
- EyeTechCare
Open-Angle Glaucoma, Ocular Hypertension
Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-69
To compare intraocular pressure lowering effectiveness of a combination drug vs. two individual drugs dosed alone.
- Trial name
- NCT00047515
- Testing
- Alcon Investigational Agent
- Where
- United States
- Sponsor
- Alcon Research
Open-angle Glaucoma, Ocular Hypertension
Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients
The purpose of this study is to determine the safety and IOP-lowering ability of a glaucoma therapy in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00069706
- Testing
- AL-12182 0.003% Ophthalmic Solution, AL-12182 Ophthalmic Solution Vehicle, Latanoprost 0.005% Ophthalmic Solution
- Volunteers
- 118 people
- Sponsor
- Alcon Research
Glaucoma
Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Open Angle Glaucoma
The purpose of this study is to evaluate how OTX-TP, a sustained release travoprost drug product, when placed in the canaliculus of the eyelid compares to timolol drops for the lowering of intraocular pressure (IOP) in patients…
- Trial name
- NCT01845038
- Testing
- OTX-TPa ~4µg/day over 2 mos. with natural tears drops, OTX-TPb ~3µg/day over 3 months with natural tears drops, Timolol Maleate (0.5%) dosed twice daily with punctum plug without drug
- Where
- South Africa
- Volunteers
- 41 people
- Sponsor
- Ocular Therapeutix, Inc.